A Saudi Child With Chronic Immune Thrombocytopenia and Vitiligo

被引:3
|
作者
Alhebshi, Abdulqader [1 ,2 ]
Abbas, Hasanat [3 ]
Alotaibi, Hidayah M. [3 ]
Attaf, Maryam [3 ]
Al-Yamani, Arwa [4 ]
机构
[1] Minist Natl Guard Hlth Affairs, Pediat Oncol, Madina, Saudi Arabia
[2] King Saud Bin Abdulaziz Univ Hlth Sci, Pediat, Riyadh, Saudi Arabia
[3] Minist Natl Guard Hlth Affairs, Prince Mohammad Bin Abdulaziz Hosp, Pediat, Medina, Saudi Arabia
[4] Minist Natl Guard Hlth Affairs, Princess Noorah Oncol Ctr, Pediat Hematol & Oncol, Jeddah, Saudi Arabia
关键词
tnf aip3 gene; tpo receptor agonist; citp; vitiligo; behcet; ADULTS; RITUXIMAB; PURPURA;
D O I
10.7759/cureus.9314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic immune thrombocytopenia (ITP) is less commonly found in the children presenting with ITP. Patients usually present with petechiae, purpura, or active bleeding in the form of epistaxis or hematuria. The main aim of treatment in chronic ITP is to prevent major bleeding and to increase the platelet count. High doses of corticosteroids, intravenous immunoglobulin, rituximab, and eltrombopag, a thrombopoietin receptor agonist (TPO-RA), are medications that can be used. In this report, we present a case of chronic ITP in a 12-year-old child. In addition to features of chronic ITP, he also has vitiligo around his eyes and limbs. During treatment, he was resistant to steroids and did not respond to rituximab or eltrombopag. To understand the cause of his presenting features, we did multiple diagnostic evaluations. The whole-exome sequencing raises the possibility of auto-inflammatory syndrome Behcet-like (AISBL), which is a rare genetic disorder and not frequently reported in the available medical literature. AISBL is caused by mutations in the TNFAIP3 gene. According to our best knowledge, this is the first Saudi child diagnosed with chronic ITP and vitiligo with the possibility of AISBL that needs further genetic work-up to confirm the diagnosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Chronic Refractory Immune Thrombocytopenia Is Associated With Variants in Immune Genes
    Zhao, Shasha
    Ma, Jingyao
    Zhu, Xiaojing
    Zhang, Jialu
    Wu, Runhui
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [32] Fostamatinib for persistent/chronic adult immune thrombocytopenia
    Newland, Adrian
    Lee, Eun-Ju
    McDonald, Vickie
    Bussel, James B.
    IMMUNOTHERAPY, 2018, 10 (01) : 9 - 25
  • [33] Thrombopoietin and Platelet Production in Chronic Immune Thrombocytopenia
    Kuter, David J.
    Gernsheimer, Terry B.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (06) : 1193 - +
  • [34] VITILIGO ASSOCIATED WITH AUTOIMMUNE THROMBOCYTOPENIA
    DEREURE, O
    MONPOINT, S
    DONADIO, D
    GUILHOU, JJ
    PRESSE MEDICALE, 1992, 21 (10): : 483 - 483
  • [35] Eltrombopag Benefits Children With Chronic Immune Thrombocytopenia
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (20): : 2122 - 2122
  • [36] Helicobacter pylori Infection and Chronic Immune Thrombocytopenia
    Takeuchi, Hiroaki
    Okamoto, Aoi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [37] Cyclosporin A for persistent or chronic immune thrombocytopenia in children
    Anthony P. Y. Liu
    Daniel K. L. Cheuk
    Ana H. Y. Lee
    Pamela P. W. Lee
    Alan K. S. Chiang
    S. Y. Ha
    W. C. Tsoi
    Godfrey C. F. Chan
    Annals of Hematology, 2016, 95 : 1881 - 1886
  • [38] Comorbidities in patients with persistent or chronic immune thrombocytopenia
    Enger, Cheryl
    Bennett, Dimitri
    Forssen, Ulla
    Fogarty, Patrick F.
    McAfee, Andrew T.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (02) : 289 - 295
  • [39] Autoimmune Markers in Children with Chronic Immune Thrombocytopenia
    Gucer, Tuba Nur Tahtakesen
    Aycicek, Ali
    Aydogan, Gonul
    Salcioglu, Zafer
    Yilmaz, Ebru
    Bayram, Cengiz
    Ozdemir, Gul Nihal Nihal
    BLOOD, 2018, 132
  • [40] Treatment of chronic immune thrombocytopenia in children with romiplostim
    Chaturvedi, Shruti
    McCrae, Keith R.
    LANCET, 2016, 388 (10039): : 4 - 6